10:01 AM EDT, 05/14/2024 (MT Newswires) -- Scilex Holding ( SCLX ) said Tuesday the US District Court for the District of Delaware approved the settlement between the company, its subsidiary Scilex Pharmaceuticals, and Takeda Pharmaceuticals, resolving a patent infringement lawsuit related to potential gout treatment Gloperba.

The company said the US Federal Trade Commission and US Department of Justice's 45-day review period for the settlement has ended.

Takeda filed a patent infringement lawsuit against Scilex ( SCLX ) in November 2023 after Scilex ( SCLX ) filed a supplemental new drug application with the US Food and Drug Administration to expand the label for Gloperba, its liquid colchicine product.

Scilex Holding ( SCLX ) said Tuesday the agreement also grants Scilex ( SCLX ) and its affiliates a non-exclusive license to certain Takeda patents under undisclosed terms.

Scilex Pharmaceutical has submitted a copy of the consent judgment to the US Food and Drug Administration, aiming to convert tentative approval for Gloperba's label expansion into final approval, Scilex ( SCLX ) added.

Takeda did not immediately respond to a request for comment from MT Newswires.

Price: 0.81, Change: +0.01, Percent Change: +0.63